Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636622 · ClinicalTrials.gov registry record · Phase 1
Study of Vemurafenib, Carboplatin, and Paclitaxel
A Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01636622 is a Phase 1 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 68-participant average among 10 other Advanced Cancers trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01636622, a Phase 1 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles (spots) of the skin and certain types of cancer cells. This drug may slow the growth of or kill these cells. Carboplatin is designed to slow the growth of cancer cells by stopping them from making new DNA (the genetic material of cells). Paclitaxel is designed to slow the growth of cancer cells by stopping them from dividing into new cells.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Vemurafenib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-07-09 |
| Est. Completion | 2020-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636622
The ClinicalTrials.gov registry entry for NCT01636622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 10 other Advanced Cancers trials with a reported enrollment target (69% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01636622 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01636622 about?
NCT01636622 is a clinical study titled "Study of Vemurafenib, Carboplatin, and Paclitaxel". The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (ca...
What is the current status of trial NCT01636622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-07-09. Estimated completion is 2020-04-21.
What conditions does trial NCT01636622 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT01636622?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01636622?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01636622 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
-
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
COMPLETED · Phase 1
-
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
COMPLETED · Phase 1
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.